

What is your professional role?

SITC Workshop on New Perspectives for Target Antigens in the Changing Cancer Immunotherapy Landscape Thursday, November 5, 2015

This form is for your evaluation of this educational activity. Please provide your input on the format, goals and other items that affect your meeting experience.

Please fill out circles carefully and completely, like this:

By providing your name and contact information, you will be entered into a drawing for a chance to win one of three \$100 Amazon gift cards. **Note: To receive CME credits, you** *must* fill out the evaluation along with your contact information.

| Clinical Come Clinical /Dunaticina | | | | | | | |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| Oncologist | \circ | Clinical Care: Physician Assistant | \bigcirc | Scientific Research: Basic | | | |
| Clinical Care: Nurse | \bigcirc | Clinical Care: Social Worker | \bigcirc | Scientific Research: Clinical | | | |
| Clinical Care: Nurse Practitioner | \bigcirc | Clinical Care: Other | \bigcirc | Scientific Research: Translational | | | |
| Clinical Care: Patient Advocate | \bigcirc | Industry | \bigcirc | Other | | | |
| Clinical Care: Pharmacist | \bigcirc | Scientist-in-Training/Student | | | | | |
| ich of the following best describes | your <i>p</i> | primary work setting? | | | | | |
| Academic Medical Center | \bigcirc | Community Hospital without Training Program | \bigcirc | Government/Regulatory | | | |
| Clinic Group Independent | \circ | Industry/Biotech (1-50 Employees) | \circ | Solo Private Practice | | | |
| Clinic Group Owned | \bigcirc | Industry/Biotech (51-500 Employees) | \bigcirc | Other | | | |
| Community Hospital with Training Program | 0 | Industry/Biotech (500+ Employees) | | | | | |
| hat is your area of specialization? | | | | | | | |
| Biochemistry | \bigcirc | Internal Medicine | | Oncology, Radiation / Radiation Biology | | | |
| Cellular Biology | \bigcirc | Microbiology | | Oncology, Surgical | | | |
| Clinical Investigations/Clinical Trials | \circ | Molecular Biology | | Pathology | | | |
| Dermatology | \circ | Oncology, Hematology | | O Pharmacology/Toxicology | | | |
| Genetics and Genomics | \bigcirc | Oncology, Medical | | Stem Cell Biology | | | |
| Immunology | \bigcirc | Oncology, Other | | Transplantation | | | |
| Immunotherapy | \bigcirc | Oncology, Pediatric | | Other | | | |
| | Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Pharmacist ich of the following best describes Academic Medical Center Clinic Group Independent Clinic Group Owned Community Hospital with Training Program hat is your area of specialization? Biochemistry Cellular Biology Clinical Investigations/Clinical Trials Dermatology Genetics and Genomics Immunology | Oncologist Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Pharmacist ich of the following best describes your particular Academic Medical Center Clinic Group Independent Clinic Group Owned Community Hospital with Training Program hat is your area of specialization? Biochemistry Cellular Biology Clinical Investigations/Clinical Trials Dermatology Genetics and Genomics Immunology | Oncologist Clinical Care: Nurse Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Patient Advocate Clinical Care: Pharmacist Scientist-in-Training/Student Scientist-in-Training/Student Scientist-in-Training/Student Community Hospital without Training Program Industry/Biotech (1-50 Employees) Industry/Biotech (51-500 Employees) Industry/Biotech (51-500 Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Internal Medicine Cellular Biology Clinical Investigations/Clinical Trials Dermatology Genetics and Genomics Oncology, Hematology Genetics and Genomics Oncology, Other | Oncologist Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Pharmacist Community Hospital without Training Program Community Hospital without Training Program Industry/Biotech (1-50 Employees) Industry/Biotech (51-500 Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Cellular Biology Clinical Investigations/Clinical Trials Dermatology Cncology, Hematology Genetics and Genomics Oncology, Medical Immunology Oncology, Other | | | |



| How long have you bee | n practicing medicine (if app | olicable)? | | | | | | | |
|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|--------------------|----------------------------------|--------------|-------------------|----------------------|-------------------|--|--|
| O More than 20 years | ○ 6 – 10 years | O Less than 1 year | | | | | | | |
| ○ 11 – 20 years | ○ 1 – 5 years | | O I do not directly provide care | | | | | | |
| How many patients with | n cancer do you currently see | e each weel | (if app | licable)? | | | | | |
| O Fewer than 5 | O 16 – 25 | O 30 | 6 – 45 | | O 56 | or more | | | |
| O 6 – 15 | O 26 – 35 | O 40 | 6 – 55 | | le | | | | |
| | tional activity, I am better a | Yes | No | Some what | Not Applicable | | | | |
| | thes to the identification of turn roteomic and bioinformatics m | \circ | \bigcirc | \circ | \circ | | | | |
| | ating T cells, T cell receptors a doptive immunotherapies. | nd chimeric | antigen | 0 | 0 | 0 | 0 | | |
| Identify the opportunities of effective cancer va | and challenges associated wince | 0 | 0 | 0 | 0 | | | | |
| Describe the results of stucheckpoint blockade. | udies aimed at identifying anti | gens targete | ed by | 0 | \circ | \circ | \circ | | |
| How would you rate the | e following measures? | Strongly Agree | Agree | Unsure | Disagree | Strongly Disagree | Not Applicable | | |
| This activity met the prog educational needs. | ram goals and my | \circ | \circ | \circ | \circ | \circ | 0 | | |
| The Workshop maintained presentations that dissimmunotherapeutic a assessment of the risl presented in a balance | scussed specific gents, fair and accurate cs and benefits were | 0 | 0 | 0 | 0 | 0 | 0 | | |
| The Workshop was free fr | rom commercial bias. | 0 | \circ | \circ | \circ | 0 | 0 | | |
| The Workshop faculty we materials | re effective in presenting the | \circ | \circ | \circ | \circ | \circ | \circ | | |





| Presenter Ratings | Excellent | Very Good | Good | Fair | Poor | | | | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------------------|--------------|--------------|------------|--|--|--|--|--|--|
| Session I: Approaches used to Identify Tumor Ar | | 0000 | 3 000 | | | | | | | | |
| Elaine Mardis, PhD | \circ | \bigcirc | \bigcirc | \bigcirc | \circ | | | | | | |
| Victor H. Engelhard, PhD | \circ | \circ | \circ | \bigcirc | \circ | | | | | | |
| Sergio A. Quezada, PhD | \circ | \bigcirc | \bigcirc | \bigcirc | \circ | | | | | | |
| Session II: Characterization and Isolation of Spec | | | | | | | | | | | |
| John Haanen, PhD | \bigcirc | \bigcirc | \bigcirc | \bigcirc | \bigcirc | | | | | | |
| Eric Tran, PhD | \circ | \bigcirc | \bigcirc | \bigcirc | \bigcirc | | | | | | |
| Laurence J.N. Cooper, MD, PhD | \circ | \bigcirc | \circ | \bigcirc | \circ | | | | | | |
| Session III: Antigen Discovery: Enabling the Next Generation of Immunotherapies | | | | | | | | | | | |
| Ugur Sahin, MD | \circ | \bigcirc | \bigcirc | \circ | \circ | | | | | | |
| Alexandra Snyder Charen, MD | \circ | \bigcirc | \bigcirc | \circ | \circ | | | | | | |
| Catherine J. Wu, MD | \circ | \bigcirc | \circ | \circ | \circ | | | | | | |
| If you perceived commercial bias, please indicate the presenter and topic and/or what SITC could do to avoid such bias. | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| Based upon your participation in this activity, do you intend to change your practice behavior? (Choose only one of the following options.) I do plan to implement changes in my practice based on the information presented. My current practice has been reinforced by the information presented. I need more information before I will change my practice. | | | | | | | | | | | |
| If you plan to change your practice behavior, wh | at changes do you p | olan to imp | lement? (Ch | oose all tha | it apply.) | | | | | | |
| Apply latest guidelines | Choice of treat | tment/mana | gement app | roach | | | | | | | |
| Change in clinical trial design | Change in curr | ent practice | for referral | | | | | | | | |
| Change in pharmaceutical therapy | Change in diffe | Change in differential diagnosis | | | | | | | | | |
| Change in non-pharmaceutical therapy | Other: | J | | | | | | | | | |
| Change in diagnostic testing | | | | | | | | | | | |



| How confident are you | that you will b | e able to m | iake your intei | nded chang | es? | | | | | | |
|---------------------------------------------------------------|-------------------|--------------|-------------------------------------------|-------------------------|------------------|--------------------------------------|--|--|--|--|--|
| O Very confident | Somewhat co | onfident | O Unsure | O Not | very confident | | | | | | |
| Thinking about how yo are likely to benefit in | | | tivity will influ | ence your p | oatient care, h | now many of your patients | | | | | |
| O Fewer than 50 | (| O 100-149 | | | ○ 200 or mo | re | | | | | |
| O 50 – 99 | (| O 150-199 | | | O Not Applicable | | | | | | |
| Which of the following | do you anticip | ate will be | the primary b | arrier to im | plementing t | hese changes? | | | | | |
| O Formulary restriction | s (| O Patient a | dherence/comp | oliance | O Insurance, | financial issues | | | | | |
| ○ Time constraints | (| ○ Lack of m | t related adverse | | | | | | | | |
| System constraintssystem or other) | (healthcare | Other, pl | ease specify: | | | | | | | | |
| What topics would you | like to see add | lressed at f | uture SITC Wo | rkshops? | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| How would you rate th | e downloadabl | e SITC 2015 | 5 Meeting App | ? | | | | | | | |
| ○ Excellent | ○ Average | \circ | Poor | \bigcirc I \bigcirc | did not know it | t was available | | | | | |
| Of the following, in wh | ich form would | | r to receive th Electronic, Pap | • | nd evaluatior | is? (choose <u>only one</u>) | | | | | |
| How do you prefer to r | eceive the type | of informa | ation/educatio | n presente | d in this meet | ing? | | | | | |
| O Participating in a live | e webinar | | | \circ | Journal ar | ticles | | | | | |
| O Participating in a sel | f paced online c | ourse | | \circ | Podcasts | | | | | | |
| O Archived session rec | ordings of live e | events | | \bigcirc | Other: | | | | | | |
| Attending a live ever | nt | | | | | | | | | | |
| What social media tech | nologies do yo | u use profe | essionally? (Fill | in all that a | pply.) | | | | | | |
| ○ LinkedIn | \circ | YouTube | | \circ | Pinterest | | | | | | |
| O Facebook | \circ | OncologyT | ube | 0 | Blogs | | | | | | |
| O Twitter | \circ | Instagram | | 0 | Other: | | | | | | |
| Are you a member of S | ITC? | ○ Yes | ○No | | | | | | | | |
| | | | | | | | | | | | |

| Please provion would like to | - | | | | dress a | nd are | ea of | inter | est sł | nould | you | wish | to b | e mo | re in | volve | ed in | SITC | or |
|-----------------------------------------------|-----------|------------------|---------|--------|----------|--------------------|--------|---------|----------------|--------|--------|--------|------------|--------|--------|--------|--------|----------|--------|
| | | | | | | | | | | | | | | | | | | | |
| If SITC could | addres | s only | y ONE | Eissue | as a S | Society | in th | ne ne | xt 12 | mon | ths, v | what | shou | ıld it | be? | | | | |
| Request for (| Credit (| *requ | ired f | ields) | | | | | | | | | | | | | | | |
| O I do not wi of education | • | • | | | • | survey | for th | nis act | tivity | to hel | p de | termi | ne its | effe | ctiver | ness a | ınd gı | uide t | he typ |
| Name* | | | | | | | | | | | D | egree | , * | | | | | | |
| Organization | າ | | | | | | | | | | Sp | oecial | ty* | | | | | | |
| Address* | | | | | | | | | | | | | | | | | | | |
| City, State, Z | IP* | | | | | | | | | | | | | | | | | | |
| Telephone | | | | | | | | | | | | | | | | | | | |
| | IMI | | | | | cate w | ill be | EMA | ILED nt leg | - | | sted (| email | l add | ress* | belo | w | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | * | | | address eive yo | | | | | - | | | | | | | <u> </u> | |
| For Physiciar O I participat O I participat | ed in the | ne ent nly pa | rt of t | he act | ivity ar | nd clair | n | _ cre | | | | | | | | | | | |
| (See program | schedu | le for | sessio | n-by-s | ession | credit | inforn | natio | n) | | | | | | | | | | |

Please return completed form to the SITC registration desk or evaluation return box.





